ESMO Media Releases
ESMO-WHO Collaboration in Kazakhstan Yields Evidence-Based Approach for Closing the Gaps in Access to High-Quality Cancer Care
Open-source approach leveraging ESMO tools can inform sustainable healthcare spending to benefit national populations worldwide
Death Rates from Ovarian Cancer will Fall in the EU and UK in 2022
Death rates from ovarian cancer are predicted to fall by 17% in 2022 in the UK and by 7% in EU countries in 2022 compared to 2017
ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February
The ESMO Sarcoma & GIST Symposium 2022, will be held as a virtual event.
ESMO Immuno-Oncology Congress 2021, Geneva, Switzerland, 8-11 December
The ESMO Immuno-Oncology Congress 2021, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as an onsite and online congress.
Female Representation at the Top of the Oncology Field Has Hit a Plateau, Research Shows
Results of the ESMO Women for Oncology monitoring and authorship studies
Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations
The much-anticipated ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer has been published today in Annals of Oncology.
Early Signs of Efficacy of New Targeted Agents and Immunotherapies Reported for Multiple Cancers at ESMO Congress 2021
Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.
The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer
First concrete results presented at the ESMO Congress 2021 confirm need to promote vaccination in patients with cancer
Tyrosine Kinase Inhibitor Prolongs Progression-Free Survival in Rare Neuroendocrine Tumours
FIRSTMAPPP, the first randomised study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months
New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer
The PEACE-1 and STAMPEDE studies found that the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy lengthened survival compared to standard therapy alone.
First-Line CDK 4/6 Inhibition Shows Overall Survival Benefit for Metastatic Breast Cancer
Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) positive, HER2 negative advanced breast cancer, according to late breaking results of the MONALEESA-2 trial